Technology 62 of 266
Vaccine technology
8 EIC Accelerator winners build on Vaccine technology, 1% of the classified companies, in 1 sector and 2 industries.
8
Companies
1
Sectors
2
Industries
5
Countries
13%
Exits
13%
Show signs of scaling
Sectors
- Health8 (100%)
Industries
Companies per year of first award
2019
2020
2021
2022
2023
2024
- Vaccine technology
Show the numbers
| Companies | Vaccine technology | |
|---|---|---|
| 2019 | 4 | 4 |
| 2020 | 1 | 1 |
| 2021 | 0 | 0 |
| 2022 | 1 | 1 |
| 2023 | 1 | 1 |
| 2024 | 1 | 1 |
What happened to them (8 of 8 checked)
- Active4 (50%)
- Exit1 (13%)
- Failed1 (13%)
- Other2 (25%)
Signs of scaling
- Scaling1 (13%)
- Not scaling2 (25%)
- Scaling unclear5 (63%)
Countries
Keywords
- Acinetobacter baumannii
- Antimicrobial resistance
- Bacterial infections
- Bovine viral diarrhoea
- Brucellosis
- Cancer vaccines
- Cattle
- Head and neck cancer
- Hospital-acquired infections
- Inflammation
- Influenza
- Interleukin-6
- Klebsiella pneumoniae
- Knee osteoarthritis
- Marker vaccines
- Metachromatic leukodystrophy
- Metastasis prevention
- Multivalent vaccines
- Nucleoprotein
- Oncology
- One Health
- Osteoarthritis
- Personalised vaccines
- Prostate cancer
- Sheep and goats
- Staphylococcus aureus
- Swine dysentery
- T-cell immunity
- Universal flu vaccine
- Virus-like particles
All 8 companies using Vaccine technology
| Company | Project | Industry | Country | Cut-off | Funding | Status | Rasph |
|---|---|---|---|---|---|---|---|
| VAXDYN SL | K-VAXClinical validation of an antibiotic-resistant bacteria global vaccine platform through the first vaccine against Klebsiella pneumoniae | Biopharmaceuticals | Spain | March 2024 | Blended finance | Active | Deep dive |
| PEPTINOV SAS | Anti-IL-6A breakthrough active immunotherapy for the treatment of osteoarthritis | Biopharmaceuticals | France | June 2023 | Blended finance | Active | Deep dive |
| Immunethep S.A. | PARAGON NOVEL VACCINEParagon Novel Vaccine (PNV) an effective protection against all serotypes of five deadly bacteria to eradicate Antimicrobial Resistance (AMR) | Biopharmaceuticals | Portugal | June 2022 | Grant first | Active | Deep dive |
| OSIVAX SAS | OSIRIXRevolutionary vaccines to prevent pandemic and seasonal outbreaks of respiratory viral infections: The best-in-class UNIVERSAL multi-season influenza vaccine | Biopharmaceuticals | France | March 2020 | Blended finance | Active | Deep dive |
| Brucella Green Vac SL | BGV1New vaccine for a paradigm shift in Brucellosis, one of the world’s most widespread zoonotic diseases affecting humans | Animal health | Spain | October 2019 | Blended finance | Insolvent | Deep dive |
| MaxiVAX SA | MaxONCOA cancer vaccine to boost body’s natural defences to fight chordoma and head and neck cancer | Biopharmaceuticals | Switzerland | June 2019 | Grant only | Pivoted | Deep dive |
| RHOVAC ApS | RV001RV001: An anti-metastatic cancer vaccine | Biopharmaceuticals | Denmark | June 2019 | Grant only | Pivoted | Deep dive |
| AQUILON CYL SOCIEDAD LIMITADA | BoVLP-BVDTagged (DIVA) polyantigenic vaccine against Bovine Viral Diarrhea virus (BVDv) based on virus-Like-Particles | Animal health | Spain | January 2019 | Grant only | Acquired | Deep dive |